Logo

Repherans noktası

Kasım 2021 yayın taraması

Tedaviye özel yayınlar

      Epoprostenol

      PAH

  1. Takeuchi K et al. Successful epoprostenol withdrawal and termination with an aid of the exercise stress test in pulmonary arterial hypertension. Int J Cardiol. 2021 [Epub]. PMID:34798203.

  2. Masitentan

    PAH

  3. Vonk Noordegraaf Aet al. The REPAIR study: Effects of macitentan on RV structure and function in pulmonary arterial hypertension. JACC Cardiovasc Imaging. 2021 [Epub]. PMID:34801462.

  4. Riociguat

    PH

  5. Wang L et al. Riociguat therapy for pulmonary hypertension: A systematic review and meta-analysis. Ann Palliat Med. 2021;10(10):11117-28. PMID:34763472.
  6. Seleksipag

    PH

  7. Chen M et al. Efficacy and safety of selexipag, an oral prostacyclin receptor agonist for the treatment of pulmonary hypertension: A meta-analysis. (Review) Pulm Pharmacol Ther. 2021 [Epub]. PMID:34856365.

  8. PAH

  9. Rosenkranz S et al. The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: Insights from the GRIPHON study. Eur J Heart Fail. 2021 [Epub]. PMID:34806261.

  10. Genel PH tedavisi

    PH

  11. Scott et al. Innovative anti-inflammatory and pro-resolving strategies for pulmonary hypertension: High Blood Pressure Research Council of Australia Award 2019. (Review) Hypertension. 2021;78(5):1168-84. PMID:34565184.

  12. PAH

  13. Valentin S et al. Outcomes of patients with decreased arterial oxyhaemoglobin saturation on pulmonary arterial hypertension drugs. Eur Respir J. 2021;58(5). PMID:33875491.
  14. Sherman AE, Saggar R, Channick RN. Update on medical management of pulmonary arterial hypertension. (Review) Cardiol Clin. 2022;40(1):13-27. PMID:34809914.
  15. Kombinasyon tedavisi

    PAH

  16. Ewert R et al. Strategies for optimizing intravenous prostacyclin-analog therapy in patients with pulmonary arterial hypertension. (Review) Expert Rev Respir Med. 2021 [Epub]. PMID:34846985.
  17. Non- farmakolojik

    PH

  18. Alqassieh A et al. MILLER banding procedure for treatment of dialysis access-related Steal Syndrome, pulmonary hypertension, and heart failure. Am Surg. 2021 [Epub]. PMID:34794331.

  19. PAH

  20. Sathananthan G et al. Evolving paradigms in the treatment of atrial septal defects with pulmonary arterial hypertension. Cardiol Rev. 2021;29(6):305-9. PMID:32956165.

  21. İlişkili PAH

  22. Gazengel P et al. Double-lung transplantation followed by delayed percutaneous repair for atrial septal defect-associated pulmonary arterial hypertension. Eur Respir J. 2021 [Epub]. PMID:34737221.

  23. KTEPH

  24. Atas H et al. Balloon pulmonary angioplasty in patients with inoperable or recurrent/residual chronic thromboembolic pulmonary hypertension: A single-centre initial experience. Heart Lung Circ. 2021 [Epub]. PMID:34838454.
  25. Bergquist CS et al. Pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension: A STS database analysis. Ann Thorac Surg. 2021 [Epub]. PMID:34838740.
  26. Blanquez-Nadal M et al. Exercise hyperventilation and pulmonary gas exchange in chronic thromboembolic pulmonary hypertension: Effects of balloon pulmonary angioplasty. J Heart Lung Transplant. 2021 [Epub]. PMID:34742646.
  27. Umemoto S et al. Increased pulmonary arterial compliance after balloon pulmonary angioplasty predicts exercise tolerance improvement in inoperable CTEPH patients with lower pulmonary arterial pressure. Heart Lung. 2021;52:8-15. PMID:34801772.
  28. Serfas JD, Krasuski RA. Interventional management of chronic thromboembolic pulmonary hypertension. (Review) Cardiol Clin. 2022;40(1):103-14. PMID:34809911.
  29. Vekstein AM et al. Surgical management of chronic thromboembolic pulmonary hypertension. (Review) Cardiol Clin. 2022;40(1):89-101. PMID:34809920.

  30. Etiyolojiye özel yayınlar

    Pulmoner hipertansiyon

    Genel PH

  31. Biedermann P et al. Standardizing registry data to the OMOP Common Data Model: Experience from three pulmonary hypertension databases. BMC Med Res Methodol. 2021;21(1):238. PMID:34727871.
  32. Ebrahimi BS et al. A computational model of contributors to pulmonary hypertensive disease: Impacts of whole lung and focal disease distributions. Pulm Circ. 2021;11(4):20458940211056527. PMID:34820115.
  33. Garcia MVF et al. Outcomes and prognostic factors of decompensated pulmonary hypertension in the intensive care unit. Respir Med. 2021;190:106685. PMID:34823189.
  34. Garcia-Ribas C et al. Importance of tricuspid regurgitation velocity threshold in risk assessment of pulmonary hypertension-long-term outcome of patients submitted to aortic valve replacement. Front Cardiovasc Med. 2021;8:720643. PMID:34859063.
  35. Goncharova EA et al. Editorial: Pulmonary hypertension in the modern era: Science and clinical practice. (Editorial) Front Med (Lausanne). 2021;8:785181. PMID:34778329.
  36. Goodman R et al. Systemic arterial properties in pulmonary hypertension. Pulm Circ. 2021;11(4):20458940211055684. PMID:34804490.
  37. Hu B et al. Novel prognostic predictor for primary pulmonary hypertension: Focus on blood urea nitrogen. Front Cardiovasc Med. 2021;8:724179. PMID:34760940.
  38. Jin Q et al. Impact of the revised hemodynamic definition on the diagnosis of precapillary pulmonary hypertension: A retrospective single-center study in China. Cardiovasc Diagn Ther. 2021;11(5):1047-57. PMID:34815955.
  39. Kroeger et al. k-t accelerated multi-VENC 4D flow MRI improves vortex assessment in pulmonary hypertension. Eur J Radiol. 2021;145:110035. PMID:34801875.
  40. McCormack C et al. “It is the fear of exercise that stops me” - attitudes and dimensions influencing physical activity in pulmonary hypertension patients. Pulm Circ. 2021;11(4):20458940211056509. PMID:34777786.
  41. Pillalamarri NR et al. Patient-specific computational analysis of hemodynamics in adult pulmonary hypertension. Ann Biomed Eng. 2021 [Epub]. PMID:34799807.
  42. Tudoran C et al. Factors influencing the evolution of pulmonary hypertension in previously healthy subjects recovering from a SARS-CoV-2 infection. J Clin Med. 2021;10(22):5272. PMID:34830554.
  43. Vinke P et al. Prevalence of micronutrient deficiencies and relationship with clinical and patient-related outcomes in pulmonary hypertension types I and IV. Nutrients. 2021;13(11):3923. PMID:34836178.
  44. Xu C et al. Use of small pulmonary vascular alterations to identify different types of pulmonary hypertension: A quantitative computed tomography analysis. J Xray Sci Technol. 2021 [Epub]. PMID:34864713.
  45. Yogeswaran A et al. Risk assessment in pulmonary hypertension based on routinely measured laboratory parameters. J Heart Lung Transplant. 2021 [Epub]. PMID:34857454.
  46. Zheng Z et al. The impact of clinical treatment plan of the new definition of precapillary pulmonary hypertension. Chest. 2021;160(5):e540-e1. PMID:34743862.
  47. Wood C et al. Perioperative management of pulmonary hypertension. A review. (Review) J Crit Care Med (Targu Mures). 2021;7(2):83-96. PMID:34722909.

  48. İlişkili PH

  49. Goulabchand R et al. Cardiovascular events, sleep apnoea, and pulmonary hypertension in primary Sjögren’s Syndrome: Data from the French health insurance database. J Clin Med. 2021;10(21):5115. PMID:34768635.
  50. Jiang X et al. Clinical features and survival in Takayasu’s arteritis-associated pulmonary hypertension: A nationwide study. Eur Heart J. 2021;42(42):4298-305. PMID:34506618.
  51. Fukumoto Y. Takayasu arteritis-associated pulmonary hypertension. (Editorial) Eur Heart J. 2021;42(42):4306-8. PMID:34542609.
  52. Masa JF et al. Risk factors associated with pulmonary hypertension in obesity hypoventilation syndrome. J Clin Sleep Med. 2021 [Epub]. PMID:34755598.
  53. Mathai SC. Pulmonary hypertension associated with connective tissue disease. (Review) Cardiol Clin. 2022;40(1):29-43. PMID:34809915.

  54. Pediatrik PH

  55. Bitners AC et al. Prevalence of elevated right ventricular pressure in children with obstructive sleep apnea syndrome undergoing pulmonary hypertension screening. J Clin Sleep Med. 2021;17(11):2225-32. PMID:34027888.
  56. Chinawa JM et al. Predictors of pulmonary hypertension among children with atrial septal defects (ASD). Libyan J Med. 2022;17(1):2007603. PMID:34813403.
  57. Epstein R, Krishnan US. Management of pulmonary hypertension in the pediatric patient. (Review) Cardiol Clin. 2022;40(1):115-27. PMID:34809912.
  58. Namuyonga J, Mocumbi AO. Pulmonary hypertension in children across Africa: The silent threat. (Review) Int J Pediatr. 2021;2021:9998070. PMID:34858504.
  59. Villafranco N et al. Pulmonary hypertension in children part 1: Causes and symptoms. (Review) Am J Respir Crit Care Med. 2021;204(10):P17-P8. PMID:34779750.

  60. Pulmoner arteriyel hipertansiyon (Grup 1)

    Genel PAH

  61. Asano R et al. Prognostic value of right ventricular native T1 mapping in pulmonary arterial hypertension. PLoS One. 2021;16(11):e0260456. PMID:34843578.
  62. Boucly A et al. External validation of a refined 4-strata risk assessment score from the French pulmonary hypertension Registry. Eur Respir J. 2021 [Epub]. PMID:34737227.
  63. Cerik IB et al. New prognostic markers in pulmonary arterial hypertension: CRP to albumin ratio and uric acid. Clin Biochem. 2021 [Epub]. PMID:34788635.
  64. Chen CY et al. Pulmonary arterial hypertension in the elderly population. J Chin Med Assoc. 2021 [Epub]. PMID:34759211.
  65. Guo FX et al. The treatment of acute exacerbations of chronic obstructive pulmonary disease complicated by pulmonary arterial hypertension. Asian J Surg. 2021 [Epub]. PMID:34815152.
  66. Haddad F et al. The right heart network and risk stratification in pulmonary arterial hypertension. Chest. 2021 [Epub]. PMID:34774527.
  67. Hoeper MM et al. COMPERA 2.0: A refined 4-strata risk assessment model for pulmonary arterial hypertension. Eur Respir J. 2021 [Epub]. PMID:34737226.
  68. Mann A et al. Study of pulmonary arterial hypertension in patients of chronic kidney disease stage IV and V. J Assoc Physicians India. 2021;69(10):11-2. PMID:34781651.
  69. Moutsoglou DM. 2021 ATS BEAR Cage winning proposal: Microbiome transplant in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2021 [Epub]. PMID:34758276.
  70. Pan Y, Sun Y, He L. Predictive factors for concomitant pulmonary arterial hypertension at diagnosis of systemic lupus erythematosus in a Chinese population. Int J Rheum Dis. 2021 [Epub]. PMID:34796660.
  71. Phoophiboon V et al. Critical care management of pulmonary arterial hypertension in pregnancy: The pre-, peri- and post-partum stages. Acute Crit Care. 2021 [Epub]. PMID:34762794.
  72. Qaderi V et al. Non-invasive risk prediction based on right ventricular function in patients with pulmonary arterial hypertension. J Clin Med. 2021;10(21):5130. PMID:34768652.
  73. Saleh D et al. A systematic evaluation of quality, accuracy, and reliability of internet websites about pulmonary arterial hypertension. Ann Am Thorac Soc. 2021 [Epub]. PMID:34813417.
  74. Sarzyńska K et al. Cultural adaptation and validation of the Polish version of the Pulmonary Arterial
  75. Hypertension-Symptoms and Impact (PAH-SYMPACT) questionnaire. Kardiol Pol. 2021 [Epub]. PMID:34729736.

  76. Shoji M et al. Fibrinolytic markers could be useful predictors of severity in patients with pulmonary arterial hypertension: A retrospective study. Thromb J. 2021;19(1):78. PMID:34736457.
  77. Urbanowicz RJ et al. A semi-automated term harmonization pipeline applied to pulmonary arterial hypertension clinical trials. Methods Inf Med. 2021 [Epub]. PMID:34820791.
  78. Wessels JN et al. Right atrial function is associated with RV diastolic stiffness: RA-RV interaction in pulmonary arterial hypertension. Eur Respir J. 2021 [Epub]. PMID:34764180.
  79. Xanthouli P et al. Prognostic impact of hypochromic erythrocytes in patients with pulmonary arterial hypertension. Respir Res. 2021;22(1):288. PMID:34753505.
  80. Zhang F, Liu H. Identification of ferroptosis-associated genes exhibiting altered expression in pulmonary arterial hypertension. Math Biosci Eng. 2021;18(6):7619-30. PMID:34814266.
  81. Budev MM, Yun JJ. Advanced circulatory support and lung transplantation in pulmonary hypertension. (Review) Cardiol Clin. 2022;40(1):129-38. PMID:34809913.
  82. Cheron C et al. Sex and gender in pulmonary arterial hypertension. (Review) Eur Respir Rev. 2021;30(162). PMID:34750113.
  83. Han Z et al. The roles of immune system and autoimmunity in pulmonary arterial hypertension: A review. (Review) Pulm Pharmacol Ther. 2021 [Epub]. PMID:34740751.
  84. Hudson J, Farkas L. Epigenetic regulation of endothelial dysfunction and inflammation in pulmonary arterial hypertension. (Review) Int J Mol Sci. 2021;22(22):12098. PMID:34829978.
  85. Naeije R et al. The physiologic basis of pulmonary arterial hypertension. (Review) Eur Respir J. 2021 [Epub]. PMID:34737219.
  86. O’Leary GM. Pulmonary arterial hypertension: An overview. (Review) Nursing. 2021;51(11):43-4. PMID:34678821.
  87. Qin X et al. Proteomic analysis of pulmonary arterial hypertension. (Review) Ther Adv Chronic Dis. 2021;12:20406223211047304. PMID:34729151.
  88. Rajagopal S, Yu YA. The pathobiology of pulmonary arterial hypertension. (Review) Cardiol Clin. 2022;40(1):1-12. PMID:34809910.
  89. Tilea I et al. Critical care management of decompensated right heart failure in pulmonary arterial hypertension patients - an ongoing approach. (Review) J Crit Care Med (Targu Mures). 2021;7(3):170-83. PMID:34722920.

  90. İdiyopatik PAH

  91. Kacprzak A et al. Predictive value of chest HRCT for survival in idiopathic pulmonary arterial hypertension. Respir Res. 2021;22(1):293. PMID:34789251.
  92. Li WT et al. Association of changes in NT-proBNP, hsTnT and uric acid levels with haemodynamic changes after targeted medical therapies in patients with idiopathic pulmonary arterial hypertension. Cardiovasc J Afr. 2021;32:1-5. PMID:34851353.

  93. İlişkili PAH

  94. Al Abdi S et al. Cutaneous iontophoresis of vasoactive medications in patients with scleroderma-associated pulmonary arterial hypertension. Microcirculation. 2021 [Epub]. PMID:34741773.
  95. Chen HH et al. Factors associated with incident severe pulmonary arterial hypertension in systemic autoimmune rheumatic diseases: A nationwide study. Rheumatology (Oxford). 2021;60(11):5351-61. PMID:33547781.
  96. He YY et al. Plasma metabolomics in the perioperative period of defect repair in patients with pulmonary arterial hypertension associated with congenital heart disease. Acta Pharmacol Sin. 2021 [Epub]. PMID:34848852.
  97. Huang YX et al. The expression profiling of microRNA in systemic sclerosis-associated pulmonary arterial hypertension. Ann Transl Med. 2021;9(18):1458. PMID:34734010.
  98. Lee A et al. Anti-Ro52/TRIM21 is independently associated with pulmonary arterial hypertension and mortality in a cohort of systemic sclerosis patients. Scand J Rheumatol. 2021;50(6):469-74. PMID:33851896.
  99. Wals-Rodriguez AJ et al. Pulmonary hypertension in adults with congenital heart disease. Clinical phenotypes and outcomes in the advanced pulmonary vasodilator era. Heart Lung. 2021;51:75-81. PMID:34768115.
  100. Goldstein SA, Krasuski RA. Pulmonary hypertension in adults with congenital heart disease. (Review) Cardiol Clin. 2022;40(1):55-67. PMID:34809917.
  101. Hon SM et al. Pulmonary arterial hypertension in patients infected with the human immunodeficiency virus. (Review) Cardiol Clin. 2022;40(1):45-54. PMID:34809916.

  102. Pediatrik PAH

  103. Canbeyli FH et al. Health-related quality of life and parental depression in children with pulmonary arterial hypertension. Pediatr Pulmonol. 2021 [Epub]. PMID:34842358.
  104. García-Aguilar H et al. Healthcare resource utilization and costs in pediatric pulmonary arterial hypertension in a third-level hospital in Mexico. J Comp Eff Res. 2021;10(16):1251-7. PMID:34585624.
  105. Rong X et al. Post-interventional evaluation and follow-up in children with patent ductus arteriosus complicated with moderate to severe pulmonary arterial hypertension: A retrospective study. Front Cardiovasc Med. 2021;8:693414. PMID:34859061.
  106. Sun XZ et al. Serum expression of Rho kinase, endothelin-1, and nitric oxide in pediatric patients with congenital heart disease accompanied by pulmonary hypertension. Asian J Surg. 2021 [Epub]. PMID:34844829.

  107. COVID-19 ve PAH

  108. Farmakis IT et al. Incidence and outcomes of COVID-19 in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Data from the Hellenic pulmOnary hyPertension rEgistry (HOPE). Hellenic J Cardiol. 2021 [Epub]. PMID:34843997.

  109. Sol kalp hastalığına bağlı PH (2)

  110. Bayram Z et al. Effect of group 2 pulmonary hypertension subgroups on outcomes: Impact of the updated definition of pulmonary hypertension. Heart Lung Circ. 2021 [Epub]. PMID:34756531.
  111. Daines B et al. The clinical associations with cardiomegaly in patients undergoing evaluation for pulmonary hypertension. J Community Hosp Intern Med Perspect. 2021;11(6):787-92. PMID:34804392.
  112. Alamri AK et al. Left heart disease-related pulmonary hypertension. (Review) Cardiol Clin. 2022;40(1):69-76. PMID:34809918.

  113. Akciğer hastalıkları ve/veya hipoksiye bağlı PH (Grup 3)

  114. Aaronson PI. Pulmonary hypertension associated with chronic hypoxia: Just ASIC-ness? J Physiol. 2021;599(21):4731-2. PMID:34533831.
  115. Cai H, Liu H. Immune infiltration landscape and immune-marker molecular typing of pulmonary fibrosis with pulmonary hypertension. BMC Pulm Med. 2021;21(1):383. PMID:34823498.
  116. Yan L et al. The clinical characteristics of patients with pulmonary hypertension combined with obstructive sleep apnoea. BMC Pulm Med. 2021;21(1):378. PMID:34802431.
  117. Ahmad K et al. Lung disease-related pulmonary hypertension. (Review) Cardiol Clin. 2022;40(1):77-88. PMID:34809919.

  118. KTEPH ve diğer pulmoner arter obstrüksiyonları (4)

  119. Boon G et al. Identification of chronic thromboembolic pulmonary hypertension on CTPAs performed for diagnosing acute pulmonary embolism depending on level of expertise. Eur J Intern Med. 2021;93:64-70. PMID:34294517.
  120. de Perrot M et al. Evaluation and management of patients with chronic thromboembolic pulmonary hypertension - consensus statement from the ISHLT. J Heart Lung Transplant. 2021;40(11):1301-26. PMID:34420851.
  121. Hu S et al. Development and validation of a nomogram for predicting the long-term survival in patients with chronic thromboembolic pulmonary hypertension. Am J Cardiol. 2021 [Epub]. PMID:34774286.
  122. Imtiaz S et al. Clinical and physiological characteristics of, medically treated, chronic thromboembolic pulmonary hypertension patients in Saudi Arabia: A single center experience. Ann Thorac Med. 2021;16(4):347-53. PMID:34820022.
  123. Kerr KM et al. Results from the United States Chronic Thromboembolic Pulmonary Hypertension Registry: Enrollment characteristics and 1-year follow-up. Chest. 2021;160(5):1822-31. PMID:34090871.
  124. Ma RZ et al. A feasibility study on using single-photon emission computed tomography pulmonary perfusion/ventilation imaging for the diagnosis of chronic thromboembolic pulmonary hypertension and patient risk assessment. Int J Gen Med. 2021;14:8029-38. PMID:34785945.
  125. McInnis MC et al. Global trends in chronic thromboembolic pulmonary hypertension clinical trials and dissemination of results. Pulm Circ. 2021;11(4):20458940211059994. PMID:34820116.
  126. Pang W et al. Higher incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism in Asians than in Europeans: A meta-analysis. Front Med (Lausanne). 2021;8:721294. PMID:34765615.
  127. Peters AC et al. Temporal trends in right heart strain in patients undergoing pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension. Echocardiography. 2021;38(11):1932-40. PMID:34747056.
  128. Potępa MA et al. Three-dimensional rotational angiography in diagnosis of chronic thromboembolic pulmonary hypertension. Postepy Kardiol Interwencyjnej. 2021;17(3):327-9. PMID:34819975.
  129. Rosen K et al. Chronic thromboembolic pulmonary hypertension in patients with antiphospholipid syndrome: Risk factors and management. J Heart Lung Transplant. 2021 [Epub]. PMID:34836752.
  130. Schüßler A et al. Evaluation of diagnostic accuracy and radiation exposure of dual-energy computed tomography (DECT) in the course of chronic thromboembolic pulmonary hypertension (CTEPH). Rofo. 2021;193(11):1318-26. PMID:34139779.
  131. Wang F et al. Identification of a novel gene correlated with vascular smooth muscle cells proliferation and migration in chronic thromboembolic pulmonary hypertension. Front Physiol. 2021;12:744219. PMID:34858201.
  132. Lang IM. Results from the United States Chronic Thromboembolic Pulmonary Hypertension Registry: Pulmonary endarterectomy first! (Editorial) Chest. 2021;160(5):1599-601. PMID:34743844.
  133. Nossent EJ et al. Chronic thromboembolic pulmonary hypertension anno 2021. (Review) Curr Opin Cardiol. 2021;36(6):711-9. PMID:34433194.

  134. Belirsiz ve/veya çok faktörlü mekanizmalara sahip PH (5)

  135. Currie BM et al. Symptoms, impacts, and suitability of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT™) questionnaire in patients with sarcoidosis-associated pulmonary hypertension (SAPH): A qualitative interview study. BMC Pulm Med. 2021;21(1):365. PMID:34772372.
  136. SSc-DU

  137. Colalillo A et al. Color Doppler Ultrasonography of digital arteries and digital ulcers development in systemic sclerosis. Microvasc Res. 2021;138:104210. PMID:34146581.
  138. Vivekanantham A et al. Associations with digital pitting in patients with systemic sclerosis: Results of a retrospective analysis. Scand J Rheumatol. 2021 [Epub]. PMID:34727825.
  139. Herrick AL. Raynaud’s phenomenon and digital ulcers: Advances in evaluation and management. (Review) Curr Opin Rheumatol. 2021;33(6):453-62. PMID:34420003.
  140. Starnoni M et al. Systemic sclerosis cutaneous expression: Management of skin fibrosis and digital ulcers. (Review) Ann Med Surg (Lond). 2021;71:102984. PMID:34840747.

Hazırlama tarihi: Aralık 2021

CP-288285